These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1163 related articles for article (PubMed ID: 20450242)

  • 21. Treatment of acute naloxone-precipitated opioid withdrawal with buprenorphine.
    Chhabra N; Aks SE
    Am J Emerg Med; 2020 Mar; 38(3):691.e3-691.e4. PubMed ID: 31753622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial.
    Ahmadi J; Jahromi MS; Ehsaei Z
    Trials; 2018 Aug; 19(1):462. PubMed ID: 30157924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double-blind, within-subject, crossover study among opioid-dependent subjects.
    Dhagudu NK; Ambekar A; Agrawal A; Rao R; Mishra AK; Jain R; Singh S
    Drug Alcohol Rev; 2020 Jul; 39(5):595-603. PubMed ID: 32162420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
    Amass L; Ling W; Freese TE; Reiber C; Annon JJ; Cohen AJ; McCarty D; Reid MS; Brown LS; Clark C; Ziedonis DM; Krejci J; Stine S; Winhusen T; Brigham G; Babcock D; Muir JA; Buchan BJ; Horton T
    Am J Addict; 2004; 13 Suppl 1(Suppl 1):S42-66. PubMed ID: 15204675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: current update.
    Soyka M
    Expert Opin Drug Deliv; 2015 Feb; 12(2):339-47. PubMed ID: 25156759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
    Alho H; Sinclair D; Vuori E; Holopainen A
    Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.
    Mendelson J; Jones RT; Welm S; Baggott M; Fernandez I; Melby AK; Nath RP
    Psychopharmacology (Berl); 1999 Jan; 141(1):37-46. PubMed ID: 9952063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.
    Rosenthal RN; Ling W; Casadonte P; Vocci F; Bailey GL; Kampman K; Patkar A; Chavoustie S; Blasey C; Sigmon S; Beebe KL
    Addiction; 2013 Dec; 108(12):2141-9. PubMed ID: 23919595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence.
    Soyka M
    Expert Opin Drug Deliv; 2012 Nov; 9(11):1409-17. PubMed ID: 23013384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single high-dose buprenorphine for opioid craving during withdrawal.
    Ahmadi J; Jahromi MS; Ghahremani D; London ED
    Trials; 2018 Dec; 19(1):675. PubMed ID: 30526648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
    Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
    J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.
    Strain EC; Harrison JA; Bigelow GE
    Clin Pharmacol Ther; 2011 Mar; 89(3):443-9. PubMed ID: 21270789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.
    Fudala PJ; Yu E; Macfadden W; Boardman C; Chiang CN
    Drug Alcohol Depend; 1998 Mar; 50(1):1-8. PubMed ID: 9589267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?
    Mendelson J; Jones RT
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S29-37. PubMed ID: 12738348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 39. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.
    Bruce RD; Govindasamy S; Sylla L; Kamarulzaman A; Altice FL
    Am J Drug Alcohol Abuse; 2009; 35(2):68-72. PubMed ID: 19212931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
    Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
    Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.